We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

88 hedge funds and large institutions have $405M invested in Supernus Pharmaceuticals in 2014 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 37 increasing their positions, 25 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

258% more call options, than puts

Call options by funds: $9.1M | Put options by funds: $2.54M

200% more funds holding in top 10

Funds holding in top 10: 2 → 6 (+4)

48% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 25

45% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 11

36% more capital invested

Capital invested by funds: $298M → $405M (+$107M)

6% more funds holding

Funds holding: 83 → 88 (+5)

Holders
88
Holders Change
+5
Holders Change %
+6.02%
% of All Funds
2.53%
Holding in Top 10
6
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+200%
% of All Funds
0.17%
New
16
Increased
37
Reduced
25
Closed
11
Calls
$9.1M
Puts
$2.54M
Net Calls
+$6.56M
Net Calls Change
+$3.23M

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$12.8M
2
MRM
Michael R. Murphy
+$10.3M
3
OHCM
Orchard Hill Capital Management
New York
+$6.85M
4
KIA
Kopp Investment Advisors
Minnesota
+$4.44M
5
NCGI
Next Century Growth Investors
Minnesota
+$4.11M

Top Sellers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$6.75M
2
JGC
J. Goldman & Co
New York
-$2.74M
3
Bank of America
Bank of America
North Carolina
-$2.23M
4
MOACM
Mutual of America Capital Management
New York
-$2.18M
5
Group One Trading
Group One Trading
Illinois
-$2.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$116M – – –
A
2
Abingworth
United Kingdom
$39.3M – – –
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$37.5M -$6.75M -757,661 -18%
MRM
4
Michael R. Murphy
$27.4M +$10.3M +1,161,315 +86%
AAP
5
Ardsley Advisory Partners
Connecticut
$19.3M +$1.56M +175,000 +11%
Ameriprise
6
Ameriprise
Minnesota
$19M -$1.11M -124,770 -7%
CCM
7
Consonance Capital Management
New York
$15.8M +$12.8M +1,440,008 New
OHCM
8
Orchard Hill Capital Management
New York
$13.9M +$6.85M +768,703 +154%
BFA
9
BlackRock Fund Advisors
California
$13.2M +$2.05M +229,881 +24%
NC
10
Northpointe Capital
Michigan
$11.2M -$446K -50,079 -5%
MOACM
11
Mutual of America Capital Management
New York
$8.84M -$2.18M -244,587 -23%
KIA
12
Kopp Investment Advisors
Minnesota
$7.28M +$4.44M +498,640 +301%
Vanguard Group
13
Vanguard Group
Pennsylvania
$7.2M +$1.15M +129,274 +24%
O
14
OrbiMed
New York
$6.35M – – –
NCGI
15
Next Century Growth Investors
Minnesota
$5.05M +$4.11M +461,467 New
IHM
16
Iguana Healthcare Management
New York
$4.11M +$2.45M +275,000 +275%
BIT
17
BlackRock Institutional Trust
California
$3.35M +$995K +111,669 +58%
State Street
18
State Street
Massachusetts
$2.94M +$260K +29,148 +12%
WA
19
Whitebox Advisors
Minnesota
$2.78M +$422K +47,327 +23%
JG
20
Jefferies Group
New York
$2.74M +$2.23M +250,472 New
EAM
21
Eventide Asset Management
Massachusetts
$2.63M +$224K +25,100 +12%
Northern Trust
22
Northern Trust
Illinois
$2.58M +$295K +33,102 +16%
RPAM
23
Rhenman & Partners Asset Management
Sweden
$2.49M +$271K +30,463 +15%
Allianz Asset Management
24
Allianz Asset Management
Germany
$2.42M +$1.97M +221,300 New
FSA
25
Franklin Street Advisors
North Carolina
$2.37M -$210K -23,550 -10%
1
2 3 4

SUPN Hedge Fund Activity: Q2 2014 in Review

88 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2014, worth a combined $405M — up 36% from $298M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new SUPN positions and 11 closed out — a net gain of 5 holders — while 37 added to existing stakes and 25 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $12.8M. The largest seller was T. Rowe Price Associates, cutting an estimated $6.75M.

  • 88 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2014, up from 83 in Q1 2014.
  • Funds reported $405M of Supernus Pharmaceuticals stock for Q2 2014, up 36% quarter-over-quarter.
  • 16 funds opened new Supernus Pharmaceuticals positions in Q2 2014 and 11 closed out, a net change of +5 holders.
  • The largest Supernus Pharmaceuticals buyer in Q2 2014 was Consonance Capital Management, an estimated $12.8M added.
  • The largest Supernus Pharmaceuticals seller in Q2 2014 was T. Rowe Price Associates, an estimated $6.75M sold.

Based on aggregated 13F filings for Q2 2014.